orlistat sold brand name xenical among others medication used treat obesity primary function preventing absorption fats human diet acting lipase inhibitor thereby reducing caloric intake intended use conjunction healthcare providersupervised reducedcalorie orlistat saturated derivative lipstatin potent natural inhibitor pancreatic lipases isolated bacterium streptomyces however due relative simplicity stability orlistat chosen lipstatin development antiobesity effectiveness orlistat promoting weight loss definite modest pooled data clinical trials suggest people given orlistat addition lifestyle modifications diet exercise lose kilograms lb taking drug course orlistat also modestly reduces blood pressure appears prevent onset type diabetes whether weight loss effects reduces incidence diabetes type ii people obese around amount lifestyle changes benefits aside however orlistat noted gastrointestinal side effects sometimes referred treatment effects include steatorrhea oily loose stools decrease time however frequently reported adverse effects australia united states european union orlistat available sale without overthecounter approval controversial united states consumer advocacy group public citizen repeatedly opposing safety efficacy generic formulations orlistat available countries australia listed medication available pharmacist without prescription since orlistat used treatment obesity amount weight loss achieved orlistat varies oneyear clinical trials subjects achieved greater decrease body mass although mass necessarily fat achieved least decrease body orlistat stopped significant number subjects regained weight reduces incidence diabetes type ii people obese around amount lifestyle changes longterm use orlistat also leads modest reduction blood pressure mean reductions mmhg systolic diastolic blood pressure orlistat contraindicated primary side effects drug gastrointestinalrelated include steatorrhea oily loose stools excessive flatus due unabsorbed fats reaching large intestine fecal incontinence frequent urgent bowel minimize effects foods high fat content avoided manufacturer advises consumers follow lowfat reducedcalorie diet oily stools flatulence controlled reducing dietary fat content somewhere region grams per manual alli makes clear orlistat treatment involves aversion therapy encouraging user associate eating fat unpleasant treatment side effects severe beginning therapy may decrease frequency also suggested decrease side effects time may associated longterm compliance lowfat may us food drug administration fda approved revised label xenical include new safety information cases severe liver injury reported rarely use analysis orlistat users ontario showed rate acute kidney injury triple study looked participants receiving orlistat uk study showed evidence increased risk liver injury incidence acute liver injury higher periods immediately immediately start orlistat treatment suggests observed increased risks liver injury linked start treatment may reflect changes health status associated decision begin treatment rather causal effect drug despite higher incidence breast cancer amongst taking orlistat early pooled clinical trial analysis delayed fda review twoyear study published found similar rates orlistat placebo versus evidence tumors predated treatment participants evidence vitro study suggest introduction specific varied preparations containing orlistat namely concurrent administration orlistat monoclonal antibody trastuzumab induce cell death breast cancer cells block fecal fat excretion promotes colon carcinogenesis results study published indicating orlistat dosage mgkg chow administered rats consuming highfat chow receiving two mgkg doses potent carcinogen produced significantly higher numbers aberrant crypt foci acf colon lesions carcinogen plus highfat chow without acf lesions believed one earliest precursors colon absorption fatsoluble vitamins fatsoluble nutrients inhibited use orlistat may reduce plasma levels ciclosporin also known cyclosporin cyclosporine trade names sandimmune gengraf neoral etc immunosuppressive drug frequently used prevent transplant rejection two drugs therefore administered orlistat also impair absorption antiarrhythmic medicines healthcare products regulatory agency mhra suggested possibility orlistat could reduce absorption antiretroviral hiv orlistat works inhibiting gastric pancreatic lipases enzymes break triglycerides lipase activity blocked triglycerides diet hydrolyzed absorbable free fatty acids instead excreted unchanged trace amounts orlistat absorbed systemically primary effect local lipase inhibition within gi tract oral dose primary route elimination feces orlistat also found inhibit thioesterase domain fatty acid synthase fas enzyme involved proliferation cancer cells normal cells however potential side effects orlistat inhibition cellular offtargets poor bioavailability might hamper application effective antitumor agent one profiling study undertook chemical proteomics approach look new cellular targets orlistat including orlistat also shows potential activity trypanosoma brucei orlistat prevents approximately dietary fat orlistat available without australia new zealand orlistat available pharmacist committee decided keep orlistat schedule drug withdrew authorization directtoconsumer xenical advertising stating increased pressure pharmacists provide orlistat consumersthis turn potential result inappropriate patterns orlistat initially approved us food drug administration april prescriptiononly january fda advisory panel voted recommend approval otc formulation orlistat sold brand name alli approval granted february alli became first weight loss drug officially sanctioned us government overthecounter consumer advocacy organization public citizen opposed overthecounter approval alli became available us june sold mg dosage prescription january european medicines agency granted approval sale orlistat without least since september tablets mg orlistat freely sold swiss drugstores formulations mg per tablet require prescription sold without one pharmacies exemption rule based list easily diagnosable us patent protection xenical originally end june extended five years us patent trademark office extension granted july expired june generic orlistat available iran brand venustat manufactured aburaihan pharmaceutical co india brands orlean eris vyfat olistat obelit orlica russia orlistat available brand names xenical roche orsotenorsoten slim krka xenalten oblpharm austria orlistat available brand name slimox malaysia orlistat available brand name cuvarlix marketed pharmaniaga philippines orlistat available brand name redoxfat plus manufactured atc healthcare times spring orlistat come short supply consequent price increases nonavailability one drugs january us food drug administration issued alert stating counterfeit versions alli sold internet contain orlistat instead contain weightloss drug sibutramine concentration sibutramine counterfeit products least twice amount recommended weight httpsenwikipediaorgwikiorlistat